Since it would be clinically valuable for a patient to eventually be able to prevent the tumor relapse, we determined if the combination therapy of IFNα-anti-PD-L1 with PD-1 blockade-mediated antitumor responses result in prolonged protective immunity. Here, PDCD1 is linked to neoplasm.